Truist Securities Maintains Buy on Inspire Medical Systems, Raises Price Target to $260
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Richard Newitter has reaffirmed a Buy rating on Inspire Medical Systems (NYSE:INSP) and increased the price target from $240 to $260. This adjustment suggests a positive outlook on the company's future performance.
December 22, 2023 | 2:51 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Truist Securities analyst Richard Newitter maintains a Buy rating on Inspire Medical Systems and raises the price target to $260, indicating a positive sentiment towards the company's stock.
The increase in price target by Truist Securities reflects a strong vote of confidence in Inspire Medical Systems' prospects. Such an endorsement from a reputable analyst is likely to be viewed positively by investors, potentially driving short-term price appreciation.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100